Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE PMR
2024-513545-37-00Phase 4Authorised
- Sponsor
- Sint Maartenskliniek
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Rituximab arm with Placebo arm (2 arms). Planned start Nov 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2024-513545-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513545-37-00.